SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Viking
Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage
biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders,
today announced that the company will participate in two
upcoming investor conferences.
Details of the company's participation are as follows:
- Stifel 2019 Healthcare Conference
Details: Viking
management will deliver a corporate presentation and participate in
1-on-1 meetings (webcast available)
Time/Date: 1:15 p.m. Eastern on
Tuesday, November 19, 2019
Location: Lotte New York Palace Hotel
- Jefferies 2019 London Healthcare Conference
Details:
Viking management will deliver a corporate presentation and
participate in 1-on-1 meetings
Time/Date: 5:20 p.m. (London time) on Thursday, November
21, 2019
Location: Waldorf Hilton London
To access the live webcast of the Stifel presentation, please
visit "Webcasts & Presentations" within the News & Events
section of Viking's Investors page at www.vikingtherapeutics.com.
Additionally, a replay of the webcast will be available on the
Viking website following the conference.
About Viking Therapeutics, Inc.
Viking
Therapeutics is a clinical-stage biopharmaceutical company focused
on the development of novel, orally available, first-in-class or
best-in-class therapies for the treatment of metabolic and
endocrine disorders. Viking's research and development
activities leverage its expertise in metabolism to develop
innovative therapeutics designed to improve patients'
lives. The company's clinical programs include VK2809, a
novel, orally available, small molecule selective thyroid hormone
receptor beta agonist for the treatment of lipid and metabolic
disorders, including non-alcoholic steatohepatitis (NASH). In
a Phase 2 trial for the treatment of non-alcoholic fatty liver
disease (NAFLD) and elevated LDL-C, patients who received VK2809
demonstrated statistically significant reductions in LDL-C and
liver fat content compared with patients who received
placebo. The company is also developing VK0214, a novel,
orally available, small molecule selective thyroid hormone receptor
beta agonist for the treatment of X-linked adrenoleukodystrophy
(X-ALD).
Viking's other programs include VK5211, an orally available,
non-steroidal selective androgen receptor modulator. In a
Phase 2 trial in patients recovering from hip fracture, patients
who received VK5211 experienced significant improvements in
measures of lean body mass compared with patients who received
placebo. Other programs also include VK0612, a first-in-class,
orally available drug candidate in Phase 2 development for the
treatment of type 2 diabetes as well as two earlier-stage programs
targeting metabolic diseases and anemia. The company holds
exclusive worldwide rights to a portfolio of five therapeutic
programs, including those noted above, which are based on small
molecules licensed from Ligand Pharmaceuticals Incorporated.
Follow Viking on Twitter @Viking_VKTX.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-300955704.html
SOURCE Viking Therapeutics, Inc.